Polysaccharide vaccines for prevention of encapsulated bacterial infections: Part 1

Infections in Medicine

Volumn 19, Issue 3, 2002, Pages 127-133

  Lee, Chi Jen ^a   Lee, Lucia H ^a   Koizumi, Kaio ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Neisseria meningitidis; Streptococcus pneumoniae; Vaccines, polysaccharide, conjugate

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; MENOMUNE A/C; MENOMUNE A/C/Y/W 135; NEISVAC C; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; BACTERIAL MEMBRANE; CELL INTERACTION; CONJUGATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERANCE; HAEMOPHILUS INFLUENZAE TYPE B; HORMONAL THERAPY; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; NEISSERIA MENINGITIDIS; PERINATAL DEVELOPMENT; SALMONELLA TYPHI; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE;

EID: 0036127616     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine
2. Epidemiology of Haemophilus influenzae type b infections in the United States
3. Meningococcal vaccines: Past, present and future
4. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines
5. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era
6. Bacterial capsular polysaccharides: Immunogenicity and vaccines
7. Rational design of conjugate vaccines
8. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines
9. Bactericidal and opsonic activity of IgG1 and IgG2 anti-capsular antibodies to Haemophilus influenzae type b
10. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine
11. Impaired immune response to polysaccharides
12. Meningococcal vaccines: Current status and future possibilities
13. Prevention and control of meningococcal disease
14. Serogroup Y meningococcal disease in Chicago, 1991-97
15. Serogroup C meningococcal outbreaks in the United States: An emerging threat
16. Meningococcal vaccines
17. Control and prevention of meningococcal disease: Recommendation of the Advisory Committee on Immunization Practice (ACIP)
18. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines
19. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: Prospects for routine immunization of infants and children
20. Evaluation of two tetravalent (A,C,Y,W135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides
21. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination
22. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomized observer-blind controlled trial
23. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults
24. Safety and immunogenicity of a serogroup A/C Neisseria meningitidis oligosaccharide-protein conjugate in young children: A randomized controlled trial
25. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine
26. Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants
27. Meningococcal conjugate vaccines: New opportunities and new challenges
28. Immunogenic response of man to group B meningococcal polysaccharide vaccines
29. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide
30. N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis
31. Phase I clinical trial with hexavalent P or A containing meningococcal outer membrane vesicle vaccine
32. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practice (ACIP)
33. Bacterial meningitis in the United States in 1995
34. Six newly recognized types of Streptococcus pneumoniae
35. Advances in pneumococcal vaccines
36. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
37. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
38. Studies on clinical application of pneumococcal vaccine. Distribution of Streptococcus pneumoniae in Japan
39. Serotypes and epidemiological study of pneumococcal infection in 18 provinces (cities) in China
40. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types
41. Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies
42. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines
43. Which pneumococcal serogroups cause the most invasive disease? Implications for conjugate vaccine formulation and use, part I
44. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines
45. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia
46. Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate
47. Maternal immunity and antibody response of neonatal mice to pneumococcal type 19F polysaccharide
48. Serum, breast milk, and infant antibody after maternal immunization with pneumococcal vaccine
49. Maternal immunization for the prevention of infections in late pregnancy and early infancy
50. Effects of maternal immunization and hormones on antibody response of neonates-immunity of bacterial polysaccharide antigens